Articles

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
New York Presbyterian & Weill Cornell, NY, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA
Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA
Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC, USA
Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA
Columbia University Medical Center, New York, NY, USA
Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA
University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA, USA
John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA
Penn State Health, Hershey, PA, USA
Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA
University of Pittsburgh Medical Center, PA, USA
Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC, USA
Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA
Tufts Medical Center, Boston, MA, USA
Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Abington Hem. Onc. Assoc., Inc., Willow Grove, PA, USA
Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI, USA
John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA
Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA
University of Pittsburgh Medical Center, PA, USA
Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Internal Medicine, Lankenau Medical Center, Wynnewood, PA, USA
Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI, USA
CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA
John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA
Columbia University Medical Center, New York, NY, USA
Abington Hem. Onc. Assoc., Inc., Willow Grove, PA, USA
University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA
Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA
Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
New York Presbyterian & Weill Cornell, NY, USA
Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA
Washington Hospital Center, DC, USA
Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
Penn State Health, Hershey, PA, USA
Tufts Medical Center, Boston, MA, USA
Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
New York Presbyterian & Weill Cornell, NY, USA
Cardinal Health, Dublin, OH, USA
Vol. 103 No. 9 (2018): September, 2018 https://doi.org/10.3324/haematol.2018.193615